USNA

USANA Health Sciences Inc. - 10-K Summary (Fiscal Year Ended Dec 30, 2006)

Business Context and Reporting Period

Company: USANA Health Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 30, 2006
Business Model: USANA develops, manufactures, and distributes science-based nutritional and personal care products via a network marketing system using independent "Associates" and direct sales to "Preferred Customers."
Segments: Operations are divided into Direct Selling (97.5% of sales) and Contract Manufacturing (2.5% of sales).
Geography: Operations span North America (65.9% of sales) and Asia Pacific (31.6% of sales). New operations commenced in Malaysia in January 2007.

Key Financial Metrics

Key Expense Ratios (2006):
- Associate Incentives: 39.1% of Net Sales ($146.3 million)
- Selling, General & Administrative (SG&A): 19.5% of Net Sales
- Research & Development: 0.9% of Net Sales ($3.2 million)

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 15.8% to $374.2 million, driven by a 15.0% increase in active Associates (153,000) and an 11.4% increase in Preferred Customers (78,000). Growth occurred in both North America (+17.7%) and Asia Pacific (+12.2%).
• Profitability: Net earnings grew 5.8% to $41.3 million. However, net earnings margin decreased from 12.1% to 11.0% due to the adoption of SFAS No. 123(R) (share-based compensation expense) and higher associate incentive payouts.
• Accounting Change: The company adopted SFAS No. 123(R) on Jan 1, 2006, recognizing $4.8 million in equity-based compensation expense (net impact of $3.2 million after tax), which reduced EPS by $0.17.
• Liquidity: Cash and cash equivalents more than doubled to $27.0 million, supported by strong operating cash flows ($60.5 million) despite $41.0 million spent on share repurchases.

Guidance, Outlook, and Risks

Management Guidance (2007):
- Net Sales: Anticipated growth of 15% to 17% compared to 2006.
- Earnings Per Share: Expected growth of 17% to 20%.
- Tax Rate: Expected effective tax rate of approximately 36.5% (up from 35.3% in 2006) due to the phase-out of the Extraterritorial Income Exclusion.

Strategic Initiatives:
- Expansion into Malaysia (commenced Jan 2007).
- Introduction of new products (e.g., TenX Antioxidant Blast) and reformulation of existing lines.
- Capital expenditures of $20–$25 million in 2007 for headquarters expansion and a new Australian facility.

Key Risks:
- Regulatory: Network marketing is subject to intense scrutiny (FTC, state laws). Changes in regulations regarding compensation plans or product claims could materially impact operations.
- Associate Dependence: Revenue relies entirely on independent Associates; high turnover and failure to recruit new Associates could stall growth.
- Foreign Exchange: 54.9% of sales are outside the U.S.; a strengthening U.S. dollar could reduce reported earnings.
- Raw Materials: Supply shortages or price increases (e.g., CoQ10 in the past) could affect margins.

Investor Verification Checklist

• Associate Turnover: Verify the rate of Associate attrition versus recruitment to ensure the 15% growth target is sustainable.
• Share Repurchase Program: Confirm the remaining balance ($39.8 million) and the company's commitment to continuing buybacks to support EPS growth.
• Capital Expenditures: Monitor the $16 million headquarters expansion and Australian facility purchase to ensure they stay within the projected $20–$25 million budget.
• Regulatory Compliance: Review any new FTC guidance or state-level "Little FTC Act" enforcement actions that could alter the compensation plan structure.
• Foreign Currency Hedging: Assess the effectiveness of hedging strategies given that over half of sales are in foreign currencies.